Transplant Equals CAR T Cell Eligibility

The next abstract is looking at from the trans form data set and so this was a randomized phase three trial of lysocaptogen marylucil or lysocel versus standard of care. In zuma seven those patients who progressed on the experimental arm came off and got commercial CAR T or didn't get CAR T  or got some other therapy. The median PFS is 5.9 months that's not great right I mean that's right in line where we were with the transcend data set. If you want to have the best outcomes in a primary or factory population or an early relapse population second line CAR T cell is where it's at.